Literature DB >> 14366997

Clinical features, pathology, and therapy of hemochromatosis.

M S KLECKNER, R M KARK, L A BAKER, A Z CHAPMAN, E KAPLAN, T J MOORE.   

Abstract

Entities:  

Keywords:  HEMOCHROMATOSIS

Mesh:

Year:  1955        PMID: 14366997     DOI: 10.1001/jama.1955.02950340001001

Source DB:  PubMed          Journal:  J Am Med Assoc        ISSN: 0002-9955


× No keyword cloud information.
  9 in total

1.  PORTAL HYPERTENSION IN HEMOCHROMATOSIS.

Authors:  R G FARMER; B H SULLIVAN
Journal:  Am J Dig Dis       Date:  1964-01

2.  HISTOGENESIS OF THE HEPATIC LESION IN PRIMARY HEMOCHROMATOSIS: WITH CONSIDERATION OF THE PSEUDO-IRON DEFICIENT STATE PRODUCED BY PHLEBOTOMIES.

Authors:  M BLOCK; G MOORE; P WASI; G HAIBY
Journal:  Am J Pathol       Date:  1965-07       Impact factor: 4.307

3.  [THE LIVER IN HEMOCHROMATOSIS].

Authors:  M KNOBLAUCH; C HEDINGER
Journal:  Virchows Arch Pathol Anat Physiol Klin Med       Date:  1963-12-09

4.  Treatment of heart failure in haemochromatosis.

Authors:  J EVANS
Journal:  Br Med J       Date:  1959-04-25

5.  Transfusional haemosiderosis simulating haemochromatosis.

Authors:  J T HUGHES; L H TRUELOVE
Journal:  J Clin Pathol       Date:  1958-03       Impact factor: 3.411

6.  Studies on the diabetic syndrome of idiopathic haemochromatosis.

Authors:  G Pozza; A Ghidoni
Journal:  Diabetologia       Date:  1968-03       Impact factor: 10.122

7.  Insulin resistant diabetes mellitus in association with haemochromatosis.

Authors:  I D Heath
Journal:  Postgrad Med J       Date:  1965-09       Impact factor: 2.401

8.  A pathological study of idiopathic haemochromatosis and its relationship to siderosis in liver cirrhosis.

Authors:  R Sinniah
Journal:  Ulster Med J       Date:  1973

Review 9.  Abdominal pain and cirrhosis at diagnosis of hemochromatosis: Analysis of 219 referred probands with HFE p.C282Y homozygosity and a literature review.

Authors:  James C Barton; J Clayborn Barton; Neha Patel; Gordon D McLaren
Journal:  PLoS One       Date:  2021-12-21       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.